Regele 1996.

Methods	Randomized, double‐blind cross‐over trial without placebo. Duration: 28 days in each arm. Not clear if single center or multicenter, based in Germany.
Participants	16 participants (9 females, 7 males) diagnosed with CF by at least 2 sweat chloride values of ≥ 70 mM and pancreatic insufficient. Age: mean 9.9 years, range 3 ‐ 27.
Interventions	Treatment A: Creon® 25000 (per capsule: 25000 U of lipase, 18000 U of amylase and 1000 U of protease). Treatment B: Panzyrtat (per capsule: 20000 U of lipase, 18000 U of amylase and 1000 U of protease). Both groups received the same number of capsules in each arm.
Outcomes	FFE, fecal chymotrypsin, fecal immunoreactive human lipase and serum immunoreactive trypsin.
Notes	Mean FFE for both the arms together was given. FFE for individual treatment periods not given.